Cellectis Hosts World's First Gene Edited Dinner in NYC NEW YORK--(BUSINESS WIRE)

Hosts World's First Gene Edited Dinner in NYC

NEW YORK--(BUSINESS WIRE)--October 31, 2016--Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS),

a biopharmaceutical company focused on developing immunotherapies based

on gene edited CAR T-cells (UCART), today announced that the Company,

along with its agricultural biotech subsidiary, Calyxt, hosted the

world's first dinner made with gene edited foods.

The dinner held on Thursday, Oct. 20, 2016 in New York required a

six-month preparation time entrusted to The Lab-Ducasse Conseil's chefs

and experts with a series of trials where the ingredients were cooked

and tasted in a variety of ways.

Attendees included university professors, doctors, reporters,

celebrities, entrepreneurs and key opinion leaders.

The six-course dinner was comprised of a variety of foods that

incorporated a selection of Calyxt's recently harvested gene edited

high-oleic soybeans and potatoes. The dinner featured Tofu and soy

burgers, Hummus soy, gilt-headbream, lemon, Oven-baked potato pie or Soy

with marinated fish and caviar, among other dishes. Calyxt uses its

innovative TALEN technology to create foods with healthier

characteristics by making precise deletions in a crop's DNA, without

adding any foreign DNA.

"This dinner - truly a meal of the 21st century -

marks a groundbreaking milestone for both Cellectis and Calyxt," said

Dr. Andr Choulika, Cellectis CEO and Calyxt president. "It not only

represents a historic moment for the food, agriculture and biotech

industries but also for people all over the world who are in search of

an answer to address some of the biggest health issues in today's

society. This meal is a clear indicator of how gene editing will

ultimately transform what we put on our plates in the near future. This

was the first harvest dinner, and millions of people will be able to

experience these same foods in the near future."

"Gene editing holds an immense potential to improve lives and nutrition

while minimizing our environmental footprint through the foods that we

produce and eat," added Federico Tripodi, Calyxt CEO. "We believe that

Calyxt's high-quality food ingredients will meet the challenges that are

related to sustainable growth and climate change, while simultaneously

addressing societal issues like obesity, diabetes and high cholesterol /

blood pressure. The possibilities are endless; every day, consumers are

increasingly mindful of the foods that they eat, and our products will

be developed to help families meet those needs. This dinner was the

first step to achieving this reality and positively impacting consumers'

lives in the months and years to come."

Photos from the meal and the full menu are available upon request.

Cellectis is a biopharmaceutical company focused on developing

immunotherapies based on gene edited CAR T-cells (UCART). The company's

mission is to develop a new generation of cancer therapies based on

engineered T-cells. Cellectis capitalizes on its 16 years of expertise

in genome engineering - based on its flagship TALEN products and

meganucleases and pioneering electroporation PulseAgile technology - to

create a new generation of immunotherapies. CAR technologies are

designed to target surface antigens expressed on cells. Using its

life-science-focused, pioneering genome-engineering technologies,

Cellectis' goal is to create innovative products in multiple fields and

with various target markets. Cellectis is listed on the Nasdaq market

(ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find

out more about us, visit our website: www.cellectis.com

Talking about gene editing? We do it. TALEN is a registered trademark

owned by the Cellectis Group.

Calyxt, Inc. is a fast-growing, consumer-oriented ag company that

utilizes its innovative, patented TALEN technology to usher in a new

era of agriculture and develop crop products with healthier

characteristics for consumers - all the while helping farmers and food

and agriculture industries reduce their environmental footprints in the

context of climate change. Calyxt believes that agricultural

technologies can have a profound, positive impact on humanity and is

looking to engage those who share this passion for food and agriculture.

Calyxt is located in Minneapolis-St. Paul, Minn., and is a wholly owned

subsidiary of Cellectis.

For further information please visit our website: www.calyxt.com

Calyxt and the corporate logo are trademarks owned by Calyxt, Inc.

This press release and the information contained herein do not

constitute an offer to sell or subscribe, or a solicitation of an offer

to buy or subscribe, for shares in Cellectis in any country. This press

release contains forward-looking statements that relate to the Company's

objectives based on the current expectations and assumptions of the

Company's management only and involve risk and uncertainties that could

cause the Company to fail to achieve the objectives expressed by the

forward-looking statements above.

Jennifer Moore, 917-580-1088

KCSA Strategic Communications

Harnest, 646-385-9008

VP of Corporate Strategy and Finance